Total Funding
26
48
Total FundingGrant raised
Growth Score 26 in past quarter
-1 pts
Heat Score 48 in past quarter
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
78871
Akanocure is a drug development company with a focus on orphan and unmet needs in oncology.
- Mohammad N. Noshi: COO & President of R&D
- Philip Fuchs: Co-Founder and CSO
About the Company
Metastasis is the spread of cancer to surrounding tissues and distant organs. It is responsible for 90% of cancer deaths. Medical efforts usually fail in managing the disease once it spreads through the body. Akanocure's mission is to find therapeutic approaches that block metastatic processes. The team at Akanocure is applying the expertise
of its members throughout the drug discovery and development process to create novel small molecules that will positively impact the lives of cancer patients.
Women Founded
Women Led
